星湖科技(600866.SH):擬投資不超過33億元建設45萬噸氨基酸及配套工程項目
格隆匯6月13日丨星湖科技(600866.SH)公佈,公司目前已成爲國內氨基酸行業排名前列的企業。但當前業務組合中動物營養類產品的營收佔比較高,業務較爲集中,整體抗行業週期波動能力仍待增強。爲更好落實公司戰略規劃,優化業務結構,進一步提升規模化生產的協同效應以降低生產成本,通過提升產品競爭力鞏固公司行業地位,公司擬以控股子公司黑龍江伊品生物科技有限公司(簡稱“黑龍江伊品生物”)、黑龍江伊品能源有限公司(簡稱“黑龍江伊品能源”)爲建設主體,以自有或自籌資金投資不超過33億元建設45萬噸氨基酸及配套工程項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.